ReviewEJNMMI radiopharmacy and chemistry2017
Pretargeting for imaging and therapy in oncological nuclear medicine.
Review in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Article
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- A simplified, robust protocol for [Scientific reports · 2025Article
- SyntheticRSC medicinal chemistry · 2024Review
- Bioorthogonal Radiolabeling of Azide-Modified Bacteria Using [Bioconjugate chemistry · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Fully automated radiolabeling of [EJNMMI radiopharmacy and chemistry · 2023Article
- Development of a Cytotoxic Antibody-Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells.International journal of molecular sciences · 2023Article
- Efficacy of HER2-Targeted IntraperitonealJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Click-to-Release: Cleavable Radioimmunoimaging with [Theranostics · 2023Article
- Investigation of Copper-64-Based Host-Guest Chemistry Pretargeted Positron Emission Tomography.Molecular pharmaceutics · 2022Article
- A proof-of-concept study on the use of a fluorescein-basedEJNMMI radiopharmacy and chemistry · 2022Article
- Radiotheranostic Agents in Hematological Malignancies.Frontiers in immunology · 2022Review
- Review
- Dual-Modality PET-SPECT Image-Guided Pretargeting Delivery in HER2(+) Breast Cancer Models.Biomacromolecules · 2021Article
- Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Cucurbituril-Ferrocene: Host-Guest Based Pretargeted Positron Emission Tomography in a Xenograft Model.Bioconjugate chemistry · 2021Article
- IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications.Molecules (Basel, Switzerland) · 2021Review
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles.
resultsWe have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibody-oligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting.
conclusionsWhile pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.